See the DrugPatentWatch profile for Breztri
Breztri Aerosphere is administered as a 180 mcg dose of budesonide, 9.6 mcg of glycopyrrolate, and 14.4 mcg of formoterol fumarate dihydrate per inhalation [1]. Patients are instructed to inhale the contents of one actuation twice daily [1].
How is Breztri Aerosphere used?
Breztri Aerosphere is a triple-therapy inhaler used for the maintenance treatment of patients with moderate to very severe chronic obstructive pulmonary disease (COPD) who are already receiving treatment with both budesonide and formoterol fumarate [1]. It delivers budesonide, a corticosteroid, glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA) [1]. The medication is delivered via a metered-dose inhaler designed to be inhaled [1].
What is the active ingredient in Breztri?
Breztri Aerosphere contains three active ingredients: budesonide, glycopyrrolate, and formoterol fumarate dihydrate [1]. Budesonide is an inhaled corticosteroid that helps reduce inflammation in the airways. Glycopyrrolate is a LAMA that helps relax airway muscles, making breathing easier. Formoterol fumarate is a LABA that also helps relax airway muscles and keeps them open [1].
What are the potential side effects of Breztri?
Common side effects associated with Breztri Aerosphere include nasopharyngitis (common cold symptoms), pneumonia, oral candidiasis (thrush), hoarseness, bruising, and diarrhea [1]. Serious side effects can include an increased risk of pneumonia, paradoxical bronchospasm, hypercorticism and adrenal suppression, and serious allergic reactions [1]. Patients using Breztri should be monitored for signs of pneumonia and thrush, and discontinuing the medication if paradoxical bronchospasm occurs [1].
What precautions should be taken with Breztri?
Individuals using Breztri Aerosphere should be aware of potential risks such as an increased risk of pneumonia, especially in patients with COPD, as well as the possibility of oral candidiasis and hypercorticism [1]. Caution is advised for patients with cardiovascular disorders, seizure disorders, or hyperthyroidism [1]. The medication is not indicated for the relief of acute bronchospasm [1].
When does patent protection for Breztri expire?
Information regarding the patent expiration for Breztri Aerosphere is available through resources that track drug patents [2]. For detailed insights into the patent landscape and exclusivity periods for Breztri, DrugPatentWatch.com provides comprehensive data [2].